| 000 | 01781 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250518045918.0 | ||
| 264 | 0 | _c20200525 | |
| 008 | 202005s 0 0 eng d | ||
| 022 | _a1750-7448 | ||
| 024 | 7 |
_a10.2217/imt-2019-0057 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSuez, Daniel | |
| 245 | 0 | 0 |
_aSafety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents. _h[electronic resource] |
| 260 |
_bImmunotherapy _c08 2019 |
||
| 300 |
_a1057-1065 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xepidemiology |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xtherapeutic use |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNorth America |
| 650 | 0 | 4 |
_aPrimary Immunodeficiency Diseases _xdrug therapy |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aKriván, Gergely | |
| 700 | 1 | _aJolles, Stephen | |
| 700 | 1 | _aStein, Mark | |
| 700 | 1 | _aGupta, Sudhir | |
| 700 | 1 | _aParis, Kenneth | |
| 700 | 1 | _avan Hagen, P Martin | |
| 700 | 1 | _aBrodszki, Nicholas | |
| 700 | 1 | _aEngl, Werner | |
| 700 | 1 | _aLeibl, Heinz | |
| 700 | 1 | _aMcCoy, Barbara | |
| 700 | 1 | _aYel, Leman | |
| 773 | 0 |
_tImmunotherapy _gvol. 11 _gno. 12 _gp. 1057-1065 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/imt-2019-0057 _zAvailable from publisher's website |
| 999 |
_c29864630 _d29864630 |
||